Oxitropium, identified by its CAS number 99571-64-9, is a synthetic anticholinergic agent primarily used in the treatment of respiratory conditions such as chronic obstructive pulmonary disease (COPD) and asthma. It functions by inhibiting the action of acetylcholine on muscarinic receptors in the airways, leading to bronchodilation and improved airflow. Oxitropium is characterized by its ability to reduce bronchospasm and is often administered via inhalation to maximize local effects while minimizing systemic side effects. The compound is typically presented as a white to off-white powder and is soluble in water, which facilitates its use in aerosol formulations. Its pharmacokinetic profile includes a relatively rapid onset of action, making it effective for acute symptom relief. As with other anticholinergic medications, potential side effects may include dry mouth, throat irritation, and urinary retention, particularly in sensitive populations. Overall, Oxitropium represents a valuable therapeutic option in the management of obstructive airway diseases.

Oxitropium

99571-64-9: 3-Oxa-9-azoniatricyclo[3.3.1.02,4]nonane, 9-ethyl-7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9-methyl-, stereoisomer, Oxitropium, stereoisomer of 9-Ethyl-7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane, 3-Oxa-9-azatricyclo[3.3.1.02,4]nonane, 3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane deriv.

CAS 99571-64-9: Oxitropium

Oxitropium bromide EP Impurity C

Ref: ST-EA-CP-O41003